Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Madsen Julia	2. Date of Event Requiring Statement (MM/DD/YYYY) 7/28/2020	3. Issuer Name and Ticker or Trading Symbol STERIS plc [STE]
(Last)        (First)        (Middle) C/O 70 SIR ROGER'S QUAY	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Senior VP, Life Sciences /
(Street) DUBLIN, L2 2       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3245 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(2)	5/31/2023	Ordinary Shares	1100	$45.34	D
Employee Stock Option (right to buy)	(2)	5/30/2024	Ordinary Shares	800	$53.52	D
Employee Stock Option (right to buy)	(2)	5/28/2025	Ordinary Shares	700	$66.15	D
Employee Stock Option (right to buy)	(2)	6/1/2026	Ordinary Shares	2700	$69.72	D
Employee Stock Option (right to buy)	(3)	5/30/2027	Ordinary Shares	3252	$77.07	D
Employee Stock Option (right to buy)	(4)	5/31/2028	Ordinary Shares	2872	$114.22	D
Employee Stock Option (right to buy)	(5)	5/31/2029	Ordinary Shares	2136	$147.05	D
Employee Stock Option (right to buy)	(6)	6/1/2030	Ordinary Shares	2984	$182.22	D

Explanation of Responses:
(1)	1,318 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 308 on June 1, 2021; 121 on June 1, 2021; 92 on June 1, 2021; 123 on June 1, 2021; 121 on May 31, 2022; 92 on May 31, 2022; 123 on June 1, 2022; 92 on May 31, 2023; 123 on June 1, 2023; 123 on June 3, 2024.
(2)	This option is fully vested.
(3)	This option becomes exercisable as follows: 813 May 30, 2018; 813 on May 30, 2019; 813 on May 30, 2020; and 813 on June 1, 2021.
(4)	This option becomes exercisable as follows: 718 on May 31, 2019; 718 on May 31, 2020; 718 on June 1, 2021; and 718 on May 31, 2022.
(5)	This option becomes exercisable as follows: 534 on May 31, 2020; 534 on June 1, 2021; 534 on May 31, 2022; and 534 on May 31, 2023.
(6)	This option becomes exercisable as follows: 746 on June 1, 2021; 746 on June 1, 2022; 746 on June 1, 2023; and 746 on June 3, 2024.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Madsen Julia C/O 70 SIR ROGER'S QUAY DUBLIN, L2 2			Senior VP, Life Sciences

Signatures
/s/ Ronald E. Snyder, Authorized Representative under Power of Attorney		8/3/2020
**Signature of Reporting Person		Date